Cancer is driven by a multitude of pathways resulting in the critical need to implement a multi-platform and pathway-based approach.

Validated biomarkers are required to tailor cancer therapy to individual patients. Projects in our CBmed cancer area cover the full workflow from identification, validation and translation into clinical use. We are developing a novel drug screening platform using patient-derived tumour cells (PDCs) for ex vivo testing of novel anti-cancer compounds and repurposing of available cancer drugs to enable personalised treatment for each individual patient.

The drug-screening platform will complement and support all cancer projects focusing on liquid biopsies, metabolomic profiling and in vivo imaging. To this end, all efforts are bundled to advance cancer therapy towards precision oncology services enabling effective and efficient treatment for every single patient. CBmed cancer projects aim to develop easily applicable, targeted, minimally invasive biomarkers for better diagnosis, better therapy monitoring and a more personalised treatment of patients.

Next generation drug-screening platform for precision oncology services

Aim: We will deliver a drug-screening platform using patient-derived tumour cells (PDCs) for ex-vivo testing of novel anti-cancer compounds and repurposing of available cancer drugs to enable personalised treatment.

Research projects

CBmed projects aim to develop easily applicable, targeted, minimally invasive biomarkers for better diagnosis, better therapy monitoring and a more personalized treatment of patients.

AMIN EL-HELIEBI
Area Leader Cancer

The COMET Center CBmed is funded within COMET – Competence Centers for Excellent Technologies by the Federal Ministry of Transport, Innovation and Technology (BMVIT), the Federal Ministry for Digital and Economic Affairs (BMDW), Land Steiermark (Styrian Business Promotion Agency – SFG) and Land Wien (Vienna Business Agency – WAW). The COMET program is executed by the Austrian Research Promotion Agency (FFG).

CBmed GmbH Center for Biomarker Research in Medicine
Stiftingtalstrasse 5   8010 Graz   Austria   office@cbmed.at   +43 316 385 28801

PRESS CORNER     CONTACT     IMPRINT     PRIVACY

Font Resize
Contrast